Haemonetics director granted 2,538 RSUs
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Madaus Martin D reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corp director Martin D. Madaus received a grant of 2,538 restricted stock units under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan on July 24, 2026. The RSUs vest 100% on the first anniversary of the grant date, with each unit delivering one share of common stock and 2,538 shares reported as directly owned after the award.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1, F2 | 2,538 | -- | -- |
Footnotes (2)
- F1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
- F2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Key Figures
Key Terms
restricted stock units ("RSUs") financial
contingent right financial
Long-Term Incentive Compensation Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity award did Haemonetics (HAE) director Martin D. Madaus receive?
When do the 2,538 RSUs granted to Haemonetics (HAE) director Martin D. Madaus vest?
What does each RSU granted to Haemonetics (HAE) director Martin D. Madaus represent?
Was the Haemonetics (HAE) insider equity grant made under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.